Compare NEXA & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEXA | XNCR |
|---|---|---|
| Founded | 1956 | 1997 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2017 | 2013 |
| Metric | NEXA | XNCR |
|---|---|---|
| Price | $9.69 | $14.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 10 |
| Target Price | $6.20 | ★ $22.78 |
| AVG Volume (30 Days) | 715.4K | ★ 751.8K |
| Earning Date | 02-19-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,839,970,000.00 | $150,132,000.00 |
| Revenue This Year | $4.43 | $18.81 |
| Revenue Next Year | $2.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 6.95 | ★ 38.16 |
| 52 Week Low | $4.44 | $6.92 |
| 52 Week High | $9.55 | $24.66 |
| Indicator | NEXA | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 73.34 | 33.73 |
| Support Level | $8.72 | $14.97 |
| Resistance Level | $9.25 | $15.42 |
| Average True Range (ATR) | 0.41 | 0.69 |
| MACD | 0.03 | -0.28 |
| Stochastic Oscillator | 95.11 | 1.59 |
Nexa Resources SA is a low-cost integrated zinc producer. It produces copper, silver, and gold as byproducts. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.